STAT+: Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial
Sellas' experimental blood cancer immunotherapy reduced the risk of death in clinical trial.
Sellas' experimental blood cancer immunotherapy reduced the risk of death in clinical trial.